Christine Ring's most recent trade in Nurix Therapeutics Inc was a trade of 5,787 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2026 | 5,787 | 117,037 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.72 per share. | 02 Sep 2026 | 5,787 | 14,897 | - | 8.7 | 50,463 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.69 per share. | 02 Sep 2026 | 5,387 | 9,510 | - | 25.7 | 138,417 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 26.64 per share. | 02 Sep 2026 | 400 | 9,110 | - | 26.6 | 10,655 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.05 per share. | 03 Aug 2026 | 16,589 | 9,110 | - | 23.0 | 382,358 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.72 per share. | 03 Aug 2026 | 5,787 | 25,699 | - | 8.7 | 50,463 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2026 | 5,787 | 122,824 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.38 per share. | 30 Jul 2026 | 3,847 | 19,912 | - | 23.4 | 89,954 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2026 | 3,750 | 17,329 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2026 | 3,750 | 11,250 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2026 | 3,572 | 23,759 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2026 | 3,572 | 39,303 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2026 | 2,858 | 20,009 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2026 | 2,858 | 20,187 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.56 per share. | 02 Jul 2026 | 11,008 | 13,579 | - | 23.6 | 259,366 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2026 | 5,787 | 128,611 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.72 per share. | 02 Jul 2026 | 5,787 | 24,587 | - | 8.7 | 50,463 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2026 | 5,221 | 0 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 02 Jul 2026 | 5,221 | 18,800 | - | 1.9 | 9,711 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 20.06 per share. | 25 Jun 2026 | 28,935 | 13,579 | - | 20.1 | 580,506 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 15,602 | 134,398 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.72 per share. | 25 Jun 2026 | 15,602 | 42,514 | - | 8.7 | 136,049 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.26 per share. | 25 Jun 2026 | 13,333 | 26,912 | - | 7.3 | 96,798 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 13,333 | 0 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.60 per share. | 02 Jun 2026 | 8,148 | 13,579 | - | 16.6 | 135,253 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2026 | 3,422 | 5,221 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 02 Jun 2026 | 3,422 | 21,727 | - | 1.9 | 6,365 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.96 per share. | 04 May 2026 | 8,148 | 18,305 | - | 17.0 | 138,210 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.76 per share. | 01 May 2026 | 5,394 | 26,453 | - | 16.8 | 90,407 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 3,750 | 15,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 3,750 | 32,203 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.65 per share. | 30 Apr 2026 | 3,214 | 31,847 | - | 16.6 | 53,498 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 2,858 | 22,867 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 2,858 | 35,061 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 2,000 | 28,453 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 2,000 | 0 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 15.24 per share. | 02 Apr 2026 | 8,148 | 26,453 | - | 15.2 | 124,149 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 15.44 per share. | 02 Mar 2026 | 8,148 | 34,601 | - | 15.4 | 125,793 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 93,750 | 93,750 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 42,875 | 42,875 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.66 per share. | 09 Feb 2026 | 14,261 | 42,749 | - | 16.7 | 237,618 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.58 per share. | 30 Jan 2026 | 4,333 | 57,098 | - | 16.6 | 71,852 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 3,750 | 18,750 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 3,750 | 58,572 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,859 | 61,431 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,859 | 25,725 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,000 | 54,822 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 1,925 | 0 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 1,925 | 52,822 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 17.38 per share. | 30 Jan 2026 | 88 | 57,010 | - | 17.4 | 1,529 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 20 Jan 2026 | 3,760 | 54,657 | - | 1.9 | 6,994 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.42 per share. | 20 Jan 2026 | 3,760 | 50,897 | - | 18.4 | 69,273 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 3,760 | 8,643 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2025 | 3,760 | 12,403 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 18 Dec 2025 | 3,760 | 54,657 | - | 1.9 | 6,994 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 17.87 per share. | 18 Dec 2025 | 3,560 | 51,097 | - | 17.9 | 63,603 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.56 per share. | 18 Dec 2025 | 200 | 50,897 | - | 18.6 | 3,711 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 24 Nov 2025 | 37,600 | 88,497 | - | 1.9 | 69,936 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 17.07 per share. | 24 Nov 2025 | 37,600 | 50,897 | - | 17.1 | 641,697 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2025 | 37,600 | 16,163 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 3,750 | 22,500 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 3,750 | 51,683 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 30 Oct 2025 | 3,644 | 50,897 | - | 12.8 | 46,631 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,858 | 28,584 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,858 | 54,541 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,000 | 47,933 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 1,924 | 45,933 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 1,924 | 1,925 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 30 Jul 2025 | 3,841 | 44,009 | - | 12.0 | 46,134 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 3,750 | 26,250 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 3,750 | 44,992 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,858 | 31,442 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,858 | 47,850 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,000 | 41,242 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 1,924 | 3,849 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 1,924 | 39,242 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,750 | 30,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,750 | 40,212 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 11.50 per share. | 30 Apr 2025 | 2,894 | 37,318 | - | 11.5 | 33,286 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 2,000 | 36,462 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 2,000 | 8,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,924 | 5,773 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,924 | 34,462 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 34,300 | 34,300 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 19.94 per share. | 31 Jan 2025 | 5,660 | 32,638 | - | 19.9 | 112,886 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,537 | 0 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 31 Jan 2025 | 5,537 | 38,298 | - | 1.9 | 10,299 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.86 per share. | 31 Jan 2025 | 223 | 32,761 | - | 1.9 | 415 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 223 | 53,763 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 20.48 per share. | 31 Jan 2025 | 100 | 32,538 | - | 20.5 | 2,048 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 3,750 | 33,750 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 3,750 | 35,758 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 19.81 per share. | 30 Jan 2025 | 2,929 | 32,829 | - | 19.8 | 58,014 | Common Stock |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 2,000 | 32,008 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 2,000 | 10,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 1,924 | 30,008 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Christine Ring | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 1,924 | 7,697 | - | - | Restricted Stock Units |